CPRX News and Press, Catalyst Pharmaceuticals Inc. From 11/11/19

ADPT , ADT , BREW , CBPX , CDLX , CPRX , DDOG , DOX , HALO , HCAT , HIIQ , HTHT , HUYA , KWR , MCRN , MTSI , OMER , PTE , RUN , SDC , SENS , SSTI , SWKS , TLRY , TVTY , TWOU , VRAY , VREX , YY For Seeking Alpha's full earnings season calendar, click here . ...

Yesterday, Catalyst Pharmaceuticals (NASDAQ: CPRX) announced that its flagship drug, Firdapse (amifampridine phosphate), failed to meet the primary endpoint of a late-stage trial as a treatment for congenital myasthenic syndrome, a genetically based muscle disorder that can lead to a person ...

CORAL GABLES, Fla., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...

A 20-subject Phase 3 clinical trial, CMS-001 , evaluating Catalyst Pharmaceuticals' (NASDAQ: CPRX ) Firdapse (amifampridine phosphate) in patients at least two years old with symptomatic genetically confirmed congenital myasthenic syndromes (CMS), a group of conditions characterized by mu...

CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients Results in full population across all tested subtypes of CMS did not achieve statistical significance for the primary or secondary endpoints MuSK-Myast...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Investing in small-cap stocks isn't for the faint of heart. This asset classes has historically shown higher volatility than the broader market. However, picking the right small-cap stock -- and watching it appreciate in value over time -- can pay rich dividends down the road. It isn't easy to ...

Catalyst Pharmaceuticals ( CPRX -3.1% ) is trimming losses after the disclosure of an insider purchase from its CEO and president. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Small-cap stocks can be outstanding growth vehicles for the buy-and-hold crowd. On balance, stocks with market caps below $2 billion have trounced the broader markets over the past two decades. The downside is that small-cap stocks tend to be on the volatile side and there's also a far greater...

CORAL GABLES, Fla., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, tod...